Journal of Clinical Medicine, Volume 11, Issue 8
2022 April-2 - 204 articles
Cover Story: Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressively debilitating disease. ATTR-CM occurs when TTR amyloid protein builds up in the myocardium along with different organs. To date, tafamidis is the only agent approved for ATTR-CM treatment. Furthermore, several agents, including green tea, tolcapone, and diflunisal, are used off-label in ATTR-CM patients. Novel therapies using RNA interference also offer clinical promise. Patisiran and inotersen are currently approved for ATTR-polyneuropathy of hereditary origin. Monoclonal antibodies in the early development phases carry hope for amyloid deposit clearance. This review describes current and future therapies for ATTR-CM and sheds light on the clinical development hurdles facing them. View this paper - Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
- You may sign up for email alerts to receive table of contents of newly released issues.
- PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.